MICVO Response Rate Rises to 39% as Pyxis Plots Mid-2027 Phase 3
PYXS sits 42% above its 52-week low of $1.03.
Summary
Updated Phase 1 data for MICVO in 2L+ R/M HNSCC show a 39% confirmed response rate in 33 evaluable patients as of October 14, 2026, up from the 36% cORR reported in September. Median response duration came in at 9.2 months and median PFS at 6.7 months, which the company frames as a 50% improvement over patients' most recent prior therapy. No new Grade 3 peripheral neuropathy cases were reported, and six patients with prior Grade 3 events improved — a safety update that matters for a drug meant to be used earlier in treatment. The company plans to start a global Phase 3 trial in mid-2027; more mature overall survival data are expected in the first half of 2027. This is still a small, early-stage cohort, so the read is encouraging but not confirmatory.
At the time of this announcement, PYXS was trading at $1.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $168.6M. The 52-week trading range was $1.03 to $5.55. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.